Aquestive Therapeutics Reports Mixed Q2 Results with Revenue Beat and Anaphylm Progress

Key Facts

In a move reflecting the operational challenges and growth opportunities within the biotech sector, Aquestive Therapeutics reported mixed financial results for the second quarter of 2026. The company posted an earnings per share (EPS) loss of -$0.18, missing the analyst consensus estimate of -$0.11, which represents an 80% negative surprise. However, revenue performance provided a silver lining, reaching $13.82 million and exceeding the estimated $11.42 million, driven by its proprietary PharmFilm technology.

On the operational front, the company is focusing its efforts on its drug development pipeline, confirming plans to resubmit its New Drug Application (NDA) for Anaphylm to the FDA in the third quarter of 2026. According to market data and financial reports, the firm shows strong liquidity indicators with a current ratio of 7.19, suggesting a robust capability to cover immediate liabilities despite remaining unprofitable with a negative price-to-earnings ratio of -6.78.

Looking ahead, investors are closely watching the regulatory timeline for Anaphylm as a primary catalyst for the stock in the coming months. As current price levels are unavailable at this time, market sentiment will likely be driven by these clinical milestones, alongside broader US economic indicators such as Initial Jobless Claims, which stood at 199k as of August 6, 2026, influencing risk appetite in high-growth sectors.